雄性激素剥夺疗法市场规模、份额、成长分析（按 ADT 类型、适应症、给药途径、患者人口统计、分销管道和地区）—产业预测，2025 年至 2032 年

2023 年全球雄性素剥夺疗法市场规模为 67 亿美元，预计将从 2024 年的 70.8 亿美元成长到 2032 年的 109.4 亿美元，预测期内（2025-2032 年）的复合年增长率为 5.6%。

由于前列腺癌盛行率不断上升以及人们对荷尔蒙敏感性肿瘤认识的不断加深，全球雄性激素剥夺疗法市场正在成长。药物传递方面的创新，尤其是长效注射剂和口服药物，正在增加治疗选择。老龄化社会中诊断率的提高、优惠的报销政策以及数位监控系统的使用，正在进一步扩大患者获得这些治疗方法的机会。然而，潜在的心臟副作用和高成本等挑战对发展中国家构成了重大障碍。未来的主要趋势包括整合人工智慧以优化治疗、生物相似药的兴起以及即时荷尔蒙抑制监测的进步，所有这些都将影响长期临床疗效和市场商业化。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究
• 顾客购买行为分析

雄性激素剥夺疗法市场规模（按 ADT 类型和复合年增长率） (2025-2032)

• 市场概览
• GnRH类似物
• 抗雄激素

雄性激素剥夺疗法市场规模（按适应症和复合年增长率）（2025-2032）

• 市场概览
• 局部前列腺癌
• 进行性前列腺癌

雄性激素剥夺疗法市场规模（按给药途径和复合年增长率） (2025-2032)

• 市场概览
• 肌肉注射
• 皮下注射

雄性激素剥夺疗法市场规模（按患者属性和复合年增长率） (2025-2032)

• 市场概览
• 40至60岁的男性
• 61-75岁男性
• 75岁或以上的男性

雄性激素剥夺疗法市场规模（按分销管道和复合年增长率） (2025-2032)

• 市场概览
• 医院
• 癌症专科诊所
• 网路药局
• 零售药局

雄性激素剥夺疗法市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益同比对比（2022-2024 年）

主要企业简介

• Ferring BV
• AstraZeneca
• Bayer AG
• Astellas Pharma Inc
• Johnson & Johnson
• Foresee Pharmaceuticals Co Ltd
• Viatris
• Verity Pharmaceuticals Inc
• AbbVie Inc
• Bristol-Myers Squibb Company
• Tolmar Pharmaceuticals Inc

结论和建议

Global Androgen Deprivation Therapy Market size was valued at USD 6.7 billion in 2023 and is poised to grow from USD 7.08 billion in 2024 to USD 10.94 billion by 2032, growing at a CAGR of 5.6% during the forecast period (2025-2032).

The Global Androgen Deprivation Therapy market is experiencing growth driven by the increasing incidence of prostate cancer and heightened awareness of hormone-sensitive tumors. Innovations in drug delivery, particularly long-acting injectables and oral medications, are enhancing treatment options. Improved diagnosis rates among aging populations, favorable reimbursement policies, and the use of digital monitoring systems are further expanding patient access to these therapies. Nevertheless, challenges such as potential cardiac side effects and high costs in developing countries pose significant barriers. Key future trends include the integration of AI for optimized therapies, the rise of biosimilars, and advancements in real-time hormone suppression monitoring, all of which are poised to shape long-term clinical efficacy and market commercialization.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Androgen Deprivation Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Androgen Deprivation Therapy Market Segments Analysis

Global Androgen Deprivation Therapy Market is segmented by Type of ADT, Indication, Route of Administration, Patient Demographics, Distribution Channel and region. Based on Type of ADT, the market is segmented into GnRH Analogues and Anti-androgens. Based on Indication, the market is segmented into Localized Prostate Cancer and Advanced Prostate Cancer. Based on Route of Administration, the market is segmented into Intramuscular and Subcutaneous. Based on Patient Demographics, the market is segmented into Men aged 40-60, Men aged 61-75 and Men above 75. Based on Distribution Channel, the market is segmented into Hospitals, Specialized Cancer Clinics, Online Pharmacies and Retail Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Androgen Deprivation Therapy Market

The increasing global prevalence of prostate cancer among older men is significantly driving the demand for androgen deprivation therapy. This treatment remains the preferred approach for managing hormone-sensitive prostate cancer, particularly in cases of advanced or metastatic disease. Additionally, initiatives aimed at enhancing screening programs and raising awareness around early detection contribute to the growing volumes of patients seeking this therapy. As more individuals recognize the importance of timely diagnosis and intervention, the market for androgen deprivation therapy is poised for continued growth in response to these escalating needs within the healthcare landscape.

Restraints in the Global Androgen Deprivation Therapy Market

The Global Androgen Deprivation Therapy market faces significant restraints due to the high costs associated with innovative treatments, including new oral blockers and long-acting injectables. These expenses often exceed the capabilities of standard insurance and public health budgets, particularly in developing nations. This creates a major barrier to affordability, compounded by inadequate reimbursement for patients and a lack of coordination within healthcare systems. As a result, many individuals in these regions may struggle to access necessary therapies, limiting the overall growth and potential of the market. Addressing these financial and systemic challenges is essential for improving patient access to effective treatments.

Market Trends of the Global Androgen Deprivation Therapy Market

The Global Androgen Deprivation Therapy (ADT) market is witnessing a significant shift toward new-generation oral hormone blockers, driven by patient preference for convenience and reduced clinic visits. By early 2024, oral luteinizing hormone-releasing hormone (LHRH) antagonists and antiandrogens have become first-line outpatient treatment options for prostate cancer, aligning with a broader trend toward decentralized care. This transition from injectable therapies to oral administration not only enhances patient compliance but also transforms treatment paradigms, indicating a robust growth trajectory for the ADT market. As healthcare systems adapt to these innovations, the demand for oral therapies is poised to accelerate.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Customer Buying Behavior Analysis

Global Androgen Deprivation Therapy Market Size by Type of ADT & CAGR (2025-2032)

• Market Overview
• GnRH Analogues
• Anti-androgens

Global Androgen Deprivation Therapy Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Localized Prostate Cancer
• Advanced Prostate Cancer

Global Androgen Deprivation Therapy Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Intramuscular
• Subcutaneous

Global Androgen Deprivation Therapy Market Size by Patient Demographics & CAGR (2025-2032)

• Market Overview
• Men aged 40-60
• Men aged 61-75
• Men above 75

Global Androgen Deprivation Therapy Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospitals
• Specialized Cancer Clinics
• Online Pharmacies
• Retail Pharmacies

Global Androgen Deprivation Therapy Market Size & CAGR (2025-2032)

• North America (Type of ADT, Indication, Route of Administration, Patient Demographics, Distribution Channel)
  • US
  • Canada
• Europe (Type of ADT, Indication, Route of Administration, Patient Demographics, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type of ADT, Indication, Route of Administration, Patient Demographics, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type of ADT, Indication, Route of Administration, Patient Demographics, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type of ADT, Indication, Route of Administration, Patient Demographics, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Ferring B V
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Foresee Pharmaceuticals Co Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Verity Pharmaceuticals Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tolmar Pharmaceuticals Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations